2.50
Hdl Handle:
http://hdl.handle.net/10033/582280
Title:
Herpes zoster in Germany: quantifying the burden of disease.
Authors:
Ultsch, Bernhard; Siedler, Anette; Rieck, Thorsten; Reinhold, Thomas; Krause, Gerard ( 0000-0003-3328-8808 ) ; Wichmann, Ole
Abstract:
Herpes zoster (HZ) is caused by a reactivation of the varicella-zoster-virus (VZV) and mainly affects individuals aged≥50 years. Vaccines have been licensed or are under development that can protect against HZ and its main complication postherpetic neuralgia (PHN). In Germany, the burden of disease caused by HZ is not well known. To support the decision making process related to a potential vaccination recommendation, we estimated annual HZ disease burden in people aged≥50 years in Germany by utilizing various data sources.
Affiliation:
Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
Citation:
Herpes zoster in Germany: quantifying the burden of disease. 2011, 11:173 BMC Infect. Dis.
Journal:
BMC infectious diseases
Issue Date:
2011
URI:
http://hdl.handle.net/10033/582280
DOI:
10.1186/1471-2334-11-173
PubMed ID:
21679419
Type:
Article
Language:
en
ISSN:
1471-2334
Appears in Collections:
Publications of the department of epidemiology (EPID)

Full metadata record

DC FieldValue Language
dc.contributor.authorUltsch, Bernharden
dc.contributor.authorSiedler, Anetteen
dc.contributor.authorRieck, Thorstenen
dc.contributor.authorReinhold, Thomasen
dc.contributor.authorKrause, Gerarden
dc.contributor.authorWichmann, Oleen
dc.date.accessioned2015-11-17T09:49:47Zen
dc.date.available2015-11-17T09:49:47Zen
dc.date.issued2011en
dc.identifier.citationHerpes zoster in Germany: quantifying the burden of disease. 2011, 11:173 BMC Infect. Dis.en
dc.identifier.issn1471-2334en
dc.identifier.pmid21679419en
dc.identifier.doi10.1186/1471-2334-11-173en
dc.identifier.urihttp://hdl.handle.net/10033/582280en
dc.description.abstractHerpes zoster (HZ) is caused by a reactivation of the varicella-zoster-virus (VZV) and mainly affects individuals aged≥50 years. Vaccines have been licensed or are under development that can protect against HZ and its main complication postherpetic neuralgia (PHN). In Germany, the burden of disease caused by HZ is not well known. To support the decision making process related to a potential vaccination recommendation, we estimated annual HZ disease burden in people aged≥50 years in Germany by utilizing various data sources.en
dc.language.isoenen
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshCost of Illnessen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshFemaleen
dc.subject.meshGermanyen
dc.subject.meshHerpes Zosteren
dc.subject.meshHerpes Zoster Vaccineen
dc.subject.meshHospitalizationen
dc.subject.meshHumansen
dc.subject.meshIncidenceen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshOutpatientsen
dc.subject.meshPoisson Distributionen
dc.titleHerpes zoster in Germany: quantifying the burden of disease.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalBMC infectious diseasesen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.